

Paolo Montuschi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/281811/publications.pdf>

Version: 2024-02-01

139
papers

9,010
citations

38660

50
h-index

40881

93
g-index

140
all docs

140
docs citations

140
times ranked

8794
citing authors

#	ARTICLE	IF	CITATIONS
1	Isoprostanes: markers and mediators of oxidative stress. <i>FASEB Journal</i> , 2004, 18, 1791-1800.	0.2	642
2	Exhaled 8-Isoprostane as an <i>In Vivo</i> Biomarker of Lung Oxidative Stress in Patients with COPD and Healthy Smokers. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 1175-1177.	2.5	514
3	Increased 8-Isoprostane, a Marker of Oxidative Stress, in Exhaled Condensate of Asthma Patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 160, 216-220.	2.5	491
4	Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. <i>European Respiratory Journal</i> , 2015, 46, 1308-1321.	3.1	434
5	A European Respiratory Society technical standard: exhaled biomarkers in lung disease. <i>European Respiratory Journal</i> , 2017, 49, 1600965.	3.1	432
6	8-Isoprostane as a Biomarker of Oxidative Stress in Interstitial Lung Diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 158, 1524-1527.	2.5	236
7	U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1797-1807.	1.5	236
8	Application of â€^{TM} omics technologies to biomarker discovery in inflammatory lung diseases. <i>European Respiratory Journal</i> , 2013, 42, 802-825.	3.1	234
9	Insights into Oxidative Stress: The Isoprostanes. <i>Current Medicinal Chemistry</i> , 2007, 14, 703-717.	1.2	222
10	Exhaled leukotrienes and prostaglandins in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 615-620.	1.5	210
11	Acute Effects of Air Pollution on Pulmonary Function, Airway Inflammation, and Oxidative Stress in Asthmatic Children. <i>Environmental Health Perspectives</i> , 2009, 117, 668-674.	2.8	208
12	Increased Nitrosothiols in Exhaled Breath Condensate in Inflammatory Airway Diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 163, 854-858.	2.5	191
13	Diagnostic Performance of an Electronic Nose, Fractional Exhaled Nitric Oxide, and Lung Function Testing in Asthma. <i>Chest</i> , 2010, 137, 790-796.	0.4	191
14	Increased Exhaled Cysteinyl-Leukotrienes and 8-Isoprostane in Aspirin-induced Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 166, 301-306.	2.5	186
15	Analysis of exhaled breath condensate for monitoring airway inflammation. <i>Trends in Pharmacological Sciences</i> , 2002, 23, 232-237.	4.0	171
16	Acute Effects of Air Pollution on Pulmonary Function, Airway Inflammation, and Oxidative Stress in Asthmatic Children. <i>Environmental Health Perspectives</i> , 2009, 117, 668-674.	2.8	170
17	NMR spectroscopy metabolomic profiling of exhaled breath condensate in patients with stable and unstable cystic fibrosis. <i>Thorax</i> , 2012, 67, 222-228.	2.7	157
18	Review: Analysis of exhaled breath condensate in respiratory medicine: methodological aspects and potential clinical applications. <i>Therapeutic Advances in Respiratory Disease</i> , 2007, 1, 5-23.	1.0	151

#	ARTICLE	IF	CITATIONS
19	The Electronic Nose in Respiratory Medicine. <i>Respiration</i> , 2013, 85, 72-84.	1.2	151
20	Exhaled Carbon Monoxide and Nitric Oxide in COPD. <i>Chest</i> , 2001, 120, 496-501.	0.4	149
21	Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 577-590.	1.5	140
22	Increased Exhaled 8-Isoprostane in Childhood Asthma. <i>Chest</i> , 2003, 124, 25-31.	0.4	134
23	Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in asthmatic children. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 761-767.	1.5	121
24	Diagnosing Nonimmediate Reactions to Penicillins by in vivo Tests. <i>International Archives of Allergy and Immunology</i> , 2002, 129, 169-174.	0.9	111
25	Separating Smoking-Related Diseases Using NMR-Based Metabolomics of Exhaled Breath Condensate. <i>Journal of Proteome Research</i> , 2013, 12, 1502-1511.	1.8	98
26	8-Isoprostane in Exhaled Breath Condensate and Exercise-Induced Bronchoconstriction in Asthmatic Children and Adolescents. <i>Chest</i> , 2009, 135, 66-73.	0.4	97
27	Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 347-353.	1.5	94
28	LC/MS/MS analysis of leukotriene B4 and other eicosanoids in exhaled breath condensate for assessing lung inflammation. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 1272-1280.	1.2	87
29	Exhaled breath condensate analysis in patients with COPD. <i>Clinica Chimica Acta</i> , 2005, 356, 22-34.	0.5	86
30	IL-17 ⁺ high asthma with features of a psoriasis immunophenotype. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1198-1213.	1.5	80
31	Exhaled 8-isoprostane and prostaglandin E2 in patients with stable and unstable cystic fibrosis. This work was performed at the Catholic University of the Sacred Heart, Rome, Italy, and Ospedale Pediatrico Bambino Gesù, Rome, Italy. This work was funded by the Catholic University of the Sacred Heart. <i>Free Radical Biology and Medicine</i> , 2008, 45, 913-919.	1.3	79
32	Exhaled Nitric Oxide as a Biomarker in COPD and Related Comorbidities. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	78
33	Indirect monitoring of lung inflammation. <i>Nature Reviews Drug Discovery</i> , 2002, 1, 238-242.	21.5	77
34	Pharmacological modulation of the leukotriene pathway in allergic airway disease. <i>Drug Discovery Today</i> , 2007, 12, 404-412.	3.2	76
35	Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4131-4164.	2.9	76
36	Within-day and between-day repeatability of measurements with an electronic nose in patients with COPD. <i>Journal of Breath Research</i> , 2013, 7, 017103.	1.5	75

#	ARTICLE	IF	CITATIONS
37	Identification and prospective stability of electronic nose (eNose)-derived inflammatory phenotypes in patients with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1811-1820.e7.	1.5	74
38	Effects of Montelukast Treatment and Withdrawal on Fractional Exhaled Nitric Oxide and Lung Function in Children With Asthma. <i>Chest</i> , 2007, 132, 1876-1881.	0.4	69
39	Comparison of classification methods in breath analysis by electronic nose. <i>Journal of Breath Research</i> , 2015, 9, 046002.	1.5	68
40	Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis. <i>European Respiratory Journal</i> , 2018, 51, 1702173.	3.1	67
41	Leukotrienes, Antileukotrienes and Asthma. <i>Mini-Reviews in Medicinal Chemistry</i> , 2008, 8, 647-656.	1.1	66
42	Electronic Nose and Exhaled Breath NMR-based Metabolomics Applications in Airways Disease. <i>Current Topics in Medicinal Chemistry</i> , 2016, 16, 1610-1630.	1.0	65
43	Liquid chromatography/mass spectrometry analysis of exhaled leukotriene B4 in asthmatic children. <i>Respiratory Research</i> , 2005, 6, 119.	1.4	63
44	Ion trap liquid chromatography/tandem mass spectrometry analysis of leukotriene B4 in exhaled breath condensate. <i>Rapid Communications in Mass Spectrometry</i> , 2004, 18, 2723-2729.	0.7	60
45	New perspectives in pharmacological treatment of mild persistent asthma. <i>Drug Discovery Today</i> , 2011, 16, 1084-1091.	3.2	59
46	Stratification of asthma phenotypes by airway proteomic signatures. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 70-82.	1.5	59
47	Ozone-induced increase in exhaled 8-isoprostane in healthy subjects is resistant to inhaled budesonide. <i>Free Radical Biology and Medicine</i> , 2002, 33, 1403-1408.	1.3	58
48	Anaphylaxis increases 8-iso-prostaglandin F2 α release from guinea-pig lung in vitro. <i>European Journal of Pharmacology</i> , 1999, 365, 59-64.	1.7	56
49	Long-Acting Beta-Agonists and their Association with Inhaled Corticosteroids in COPD. <i>Current Medicinal Chemistry</i> , 2013, 20, 1477-1495.	1.2	54
50	Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. <i>Drug Discovery Today</i> , 2014, 19, 1928-1935.	3.2	53
51	Urinary Leukotriene E ₄ and Prostaglandin D ₂ Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 37-53.	2.5	49
52	Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers. <i>Journal of Breath Research</i> , 2016, 10, 017102.	1.5	48
53	Dupilumab for the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 357-366.	1.9	47
54	Nuclear Magnetic Resonance-based Metabolomics Discriminates Primary Ciliary Dyskinesia from Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 229-233.	2.5	46

#	ARTICLE	IF	CITATIONS
55	Development of a Sensing Array for Human Breath Analysis Based on SWCNT Layers Functionalized with Semiconductor Organic Molecules. <i>Advanced Healthcare Materials</i> , 2020, 9, e2000377.	3.9	44
56	Role of Leukotrienes and Leukotriene Modifiers in Asthma. <i>Pharmaceuticals</i> , 2010, 3, 1792-1811.	1.7	42
57	Inhaled Muscarinic Acetylcholine Receptor Antagonists for Treatment of COPD. <i>Current Medicinal Chemistry</i> , 2013, 20, 1464-1476.	1.2	41
58	Treatable traits in the European UÅ€<scp>BIOPRED</scp> adult asthma cohorts. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 406-411.	2.7	37
59	Pharmacological treatment of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2006, 1, 409-423.	0.9	36
60	Liquid chromatographyâ€“mass spectrometry measurement of leukotrienes in asthma and other respiratory diseases. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 964, 12-25.	1.2	34
61	Triple inhaled therapy for chronic obstructive pulmonary disease. <i>Drug Discovery Today</i> , 2016, 21, 1820-1827.	3.2	30
62	Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). <i>World Allergy Organization Journal</i> , 2020, 13, 100464.	1.6	30
63	Measurement of 8-Isoprostane in Exhaled Breath Condensate. <i>Methods in Molecular Biology</i> , 2010, 594, 73-84.	0.4	30
64	Exhaled volatile organic compounds as markers for medication use in asthma. <i>European Respiratory Journal</i> , 2020, 55, 1900544.	3.1	27
65	Gallbladder emptying, plasma levels of estradiol and progesterone, and cholecystokinin secretion in liver cirrhosis. <i>Digestive Diseases and Sciences</i> , 1995, 40, 428-434.	1.1	25
66	Breathomics for Assessing the Effects of Treatment and Withdrawal With Inhaled Beclomethasone/Formoterol in Patients With COPD. <i>Frontiers in Pharmacology</i> , 2018, 9, 258.	1.6	25
67	Transcriptional regulation of kinases downstream of the T cell receptor: another immunomodulatory mechanism of glucocorticoids. <i>BMC Pharmacology & Toxicology</i> , 2014, 15, 35.	1.0	23
68	eNose breath prints as a surrogate biomarker for classifying patients with asthma by atopy. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1045-1055.	1.5	22
69	Mapping atopic dermatitis and antiâ€“IL-22 response signatures to type 2â€“low severe neutrophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 89-101.	1.5	22
70	Evidence that interleukin-1Î² and tumor necrosis factor inhibit gastric fundus motility via the 5-lipoxygenase pathway. <i>European Journal of Pharmacology</i> , 1994, 252, 253-260.	1.7	21
71	Investigational prostaglandin D2receptor antagonists for airway inflammation. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 639-652.	1.9	21
72	Exhaled Nitric Oxide Measurement in Patients Affected by Nasal Polyposis. <i>Otolaryngology - Head and Neck Surgery</i> , 2012, 147, 351-356.	1.1	20

#	ARTICLE	IF	CITATIONS
73	Methodological considerations for large-scale breath analysis studies: lessons from the U-BIOPRED severe asthma project. <i>Journal of Breath Research</i> , 2019, 13, 016001.	1.5	20
74	Inflammatory Response to Sputum Induction Measured by Exhaled Markers. <i>Respiration</i> , 2005, 72, 594-599.	1.2	19
75	The potential role of endothelial dysfunction and platelet activation in the development of thrombotic risk in COPD patients. <i>Expert Review of Hematology</i> , 2017, 10, 821-832.	1.0	19
76	Sputum proteomic signature of gastro-oesophageal reflux in patients with severe asthma. <i>Respiratory Medicine</i> , 2019, 150, 66-73.	1.3	19
77	Role of beta-blockers in patients with COPD: current perspective. <i>Drug Discovery Today</i> , 2015, 20, 129-135.	3.2	18
78	Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohort. <i>PLoS ONE</i> , 2018, 13, e0203874.	1.1	18
79	The Combined Impact of Exhaled Nitric Oxide and Sputum Eosinophils Monitoring in Asthma Treatment: A Prospective Cohort Study. <i>Current Pharmaceutical Design</i> , 2015, 21, 4752-4762.	0.9	18
80	Severe asthma: One disease and multiple definitions. <i>World Allergy Organization Journal</i> , 2021, 14, 100606.	1.6	18
81	Sleep Deprivation, Immune Suppression and SARS-CoV-2 Infection. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 904.	1.2	18
82	Pharmacotherapy of Patients with Mild Persistent Asthma: Strategies and Unresolved Issues. <i>Frontiers in Pharmacology</i> , 2011, 2, 35.	1.6	17
83	Lipid phenotyping of lung epithelial lining fluid in healthy human volunteers. <i>Metabolomics</i> , 2018, 14, 123.	1.4	17
84	Interleukin-1 β and tumour necrosis factor inhibit rat gastric fundus motility in vitro. <i>European Journal of Pharmacology</i> , 1993, 233, 303-304.	1.7	16
85	Large-Scale Label-Free Quantitative Mapping of the Sputum Proteome. <i>Journal of Proteome Research</i> , 2018, 17, 2072-2091.	1.8	16
86	Effects of vasoactive intestinal polypeptide on antigen-induced bronchoconstriction and thromboxane release in guinea pig lung. <i>British Journal of Pharmacology</i> , 1993, 109, 243-250.	2.7	15
87	Epithelial dysregulation in obese severe asthmatics with gastro-oesophageal reflux. <i>European Respiratory Journal</i> , 2019, 53, 1900453.	3.1	15
88	Metabolomic Analysis by Nuclear Magnetic Resonance Spectroscopy as a New Approach to Understanding Inflammation and Monitoring of Pharmacological Therapy in Children and Young Adults With Cystic Fibrosis. <i>Frontiers in Pharmacology</i> , 2018, 9, 595.	1.6	14
89	NMR-Based Metabolomics for the Assessment of Inhaled Pharmacotherapy in Chronic Obstructive Pulmonary Disease Patients. <i>Journal of Proteome Research</i> , 2020, 19, 64-74.	1.8	14
90	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. <i>World Allergy Organization Journal</i> , 2021, 14, 100509.	1.6	14

#	ARTICLE	IF	CITATIONS
91	Toward a Personalized Pharmacotherapy of Respiratory Diseases. <i>Frontiers in Pharmacology</i> , 2010, 1, 131.	1.6	13
92	High sputum total adiponectin is associated with low odds for asthma. <i>Journal of Asthma</i> , 2014, 51, 459-466.	0.9	13
93	Asthma similarities across ProAR (Brazil) and U-BIOPRED (Europe) adult cohorts of contrasting locations, ethnicity and socioeconomic status. <i>Respiratory Medicine</i> , 2020, 161, 105817.	1.3	13
94	Urinary metabolite profile of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study. <i>European Respiratory Journal</i> , 2022, 59, 2101733.	3.1	13
95	Vilanterol trifenate for the treatment of COPD. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 719-731.	1.0	12
96	Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umecclidinium and vilanterol in the management of COPD: the current evidence base and future prospects. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661876077.	1.0	12
97	Exploring the performance of a functionalized CNT-based sensor array for breathomics through clustering and classification algorithms: from gas sensing of selective biomarkers to discrimination of chronic obstructive pulmonary disease. <i>RSC Advances</i> , 2021, 11, 30270-30282.	1.7	12
98	A multi-omics approach to delineate sputum microbiome-associated asthma inflammatory phenotypes. <i>European Respiratory Journal</i> , 2022, 59, 2102603.	3.1	11
99	Clinical and transcriptomic features of persistent exacerbation-prone severe asthma in U-BIOPRED cohort. <i>Clinical and Translational Medicine</i> , 2022, 12, e816.	1.7	11
100	Medication Adherence in Patients With Severe Asthma Prescribed Oral Corticosteroids in the U-BIOPRED Cohort. <i>Chest</i> , 2021, 160, 53-64.	0.4	10
101	Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation. <i>European Respiratory Journal</i> , 2022, 59, 2100142.	3.1	10
102	Impulse oscillometry and nitrogen washout test in the assessment of small airway dysfunction in asthma: Correlation with quantitative computed tomography. <i>Journal of Asthma</i> , 2019, 56, 323-331.	0.9	9
103	Isoprostanes and asthma. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2006, 3, 287-292.	0.5	8
104	Editorial (Hot Topic: Drugs for Chronic Obstructive Pulmonary Disease). <i>Current Medicinal Chemistry</i> , 2013, 20, 1461-1463.	1.2	8
105	Detection and characterisation of extracellular vesicles in exhaled breath condensate and sputum of COPD and severe asthma patients. <i>European Respiratory Journal</i> , 2021, 58, 2003024.	3.1	8
106	Blood levels of vasoactive intestinal polypeptide in normal and growth retarded fetuses: relationship with acid-base and haemodynamic status. <i>Early Human Development</i> , 1995, 41, 69-77.	0.8	7
107	SIRM-SIAAIC consensus, an Italian document on management of patients at risk of hypersensitivity reactions to contrast media. <i>Clinical and Molecular Allergy</i> , 2020, 18, 13.	0.8	7
108	Comparison of two exhaled biomarkers in children with and without sleep disordered breathing. <i>Sleep Medicine</i> , 2018, 45, 83-88.	0.8	6

#	ARTICLE	IF	CITATIONS
109	Dupilumab and tezepelumab in severe refractory asthma: new opportunities. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210973.	1.1	6
110	Pharmacotherapy of asthma: regular treatment or on demand?. <i>Therapeutic Advances in Respiratory Disease</i> , 2009, 3, 175-191.	1.0	5
111	Predictive Markers of Bronchial Hyperreactivity in a Large Cohort of Young Adults With Cough Variant Asthma. <i>Frontiers in Pharmacology</i> , 2021, 12, 630334.	1.6	5
112	Tachykinin NK2 receptor antagonists decrease eicosanoid release in lung anaphylaxis. <i>European Journal of Pharmacology</i> , 1996, 313, R1-R3.	1.7	4
113	Chronic Obstructive Pulmonary Disease Phenotyping: A Possible Role for 8-Isoprostane Measurement in Exhaled Breath Condensate?. <i>Respiration</i> , 2008, 75, 134-135.	1.2	4
114	Interleukin-1 receptor antagonist displays intrinsic agonist activity on rat gastric fundus motility in vitro. <i>European Journal of Pharmacology</i> , 1995, 275, 31-37.	1.7	3
115	Measurement of Biomarkers of Oxidative Stress and Airway Inflammation in Exhaled Breath Condensate: Methodology and Potential Applications in Patients with COPD and Healthy Smokers. , 2013, , 360-381.		3
116	Characteristics of the frequent exacerbator in U-BIOPRED adult severe asthma cohort. , 2015, , .		3
117	Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 319-329.	1.9	2
118	The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 563-577.	2.5	2
119	Volatile Organic Compounds Breathprinting of U-BIOPRED Severe Asthma smokers/ex-smokers cohort. , 2017, , .		2
120	U-BIOPRED accessible handprint: combining omics platforms to identify stable asthma subphenotypes. , 2018, , .		2
121	Topological data analysis (TDA) of U-BIOPRED paediatric peripheral blood gene expression identified asthma phenotypes characterised by alternative splicing of glucocorticoid receptor (GR) mRNA. , 2018, , .		2
122	In vitro testing for lung toxicity: a method for distinguishing between immune- and non-immune-mediated reactions to xenobiotics. <i>Environmental Toxicology and Pharmacology</i> , 1996, 2, 201-205.	2.0	1
123	An investigation on e-nose platform relevance to respiratory diseases. , 2014, , .		1
124	Measures of adherence in patients with severe asthma prescribed systemic steroids in the U-BIOPRED cohort. , 2018, , .		1
125	Corrigendum to "Interleukin-1 receptor antagonist displays intrinsic agonist activity on rat gastric fundus motility in vitro" [Eur. J. Pharmacol. 275 (1995) 31-37]. <i>European Journal of Pharmacology</i> , 1995, 282, 263.	1.7	0
126	Exhaled Breath Condensate Biomarkers of Airway Inflammation and Oxidative Stress in COPD. , 2011, , 421-440.		0

#	ARTICLE	IF	CITATIONS
127	The first U-BIOPRED sputum handprint of severe asthma. , 2015, , .		0
128	The first U-BIOPRED blood handprint of severe asthma. , 2015, , .		0
129	Breathomics can discriminate between anti IgE-treated and non-treated severe asthma adults. , 2015, , .		0
130	Unbiased clustering of severe asthma patients based on exhaled breath profiles. , 2015, , .		0
131	Exhaled breath VOCs are associated with nocturnal waking in asthmatic children. , 2015, , .		0
132	Computed tomography for evaluation of the small airway disease in asthma. , 2015, , .		0
133	Effects of treatment and withdrawal with inhaled beclomethasone/formoterol on electronic nose and NMR metabolomic breathprints in patients with COPD. , 2016, , .		0
134	Late Breaking Abstract - Cluster analysis of treatable traits in the U-BIOPRED adult severe asthma cohort. , 2017, , .		0
135	Urinary metabolomics-based molecular sub-phenotyping of the U-BIOPRED asthma cohort. , 2017, , .		0
136	NMR-based metabolomics of exhaled breath condensate for assessing the effects of inhaled corticosteroids in COPD patients. , 2017, , .		0
137	Association between exhaled volatile organic compounds and urinary levels of oral corticosteroids within the U-BIOPRED Cohort. , 2018, , .		0
138	Subtypes of eosinophilic asthma with discrete gene pathway phenotypes. , 2019, , .		0
139	A NMR-based metabolomics approach to the assessment of inhaled pharmacotherapy in patients with COPD. , 2019, , .		0